Clinical Trials
Thyroid eye disease is an autoimmune inflammatory disorder that can be vision-threatening and disfiguring.
New medical therapies are emerging to prevent and treat the disabling consequences of the disease.
We are involved in multiple clinical trials aimed at providing targeted therapy for TED.
What is TED?
- Double Vision
- Bulging Eyes
- Redness & Swelling
- Inability to close the eyes
- Tearing & Irritation
Treatment costs are covered for patients who meet criteria for enrollment in Clinical Trials
You will be compensated for your time and travel
Inclusion Criteria
- Age 18 years of age or older
- Have clinical symptoms and signs of Thyroid Eye Disease
- Both men and women need to avoid becoming pregnant during study screening up to and including 100 days after the last dose of study medication
- Be willing and able to comply with all the requirements of the protocol for the entire duration of the study
Current Clinical Trials
Viridian (VRDN-001-302): NCT06179875
Viridian (VRDN-001-301): NCT05176639
Tourmaline (TOUR006-T01): NCT06088979
Immunovant (IMVT-1401-3201): NCT05517421
Horizon (HZNP-TEP-305): NCT06248619
Lassen (LASN01-CL-2201): NCT06226545
Our Team
Kimberly Cockerham, MD, FACS
Principal Investigator, Thyroid Eye Disease Clinical Trials
Neuro-ophthalmology, Oculofacial plastic Surgery & Orbital Oncology
Rocio Gonzalez Beristain, MS, MPH
Clinical Research Coordinator
VRDN-001 Clinical Study
Emma
Front Office Coordinator
Lead for Horizon/Amgen and Tourmaline
Serena
Surgical Concierge
Helps facilitate your surgery in the office or at an ambulatory surgery center.
Karen
Certified Ophthalmic Technician
Research coordinator
Lead for Viridian and Genentech
Anna Artymowicz
Clinical Fellow, 2024-2025
Sub-PI for all clinical trials
